The Albert B Sabin Vaccine Institute Inc

TO MAKE VACCINES MORE ACCESSIBLE, ENABLE INNOVATION AND EXPAND IMMUNIZATION.

VACCINE RESEARCH AND DEVELOPMENT:THE SABIN VACCINE INSTITUTE SUPPORTS INNOVATIVE TECHNOLOGIES AND APPROACHES IN VACCINE RESEARCH AND DEVELOPMENT TO COMBAT INFECTIOUS AND EMERGING THREATS TO GLOBAL HEALTH. SABIN'S RESEARCH & DEVELOPMENT STRATEGY IS TO ADVANCE THE DEVELOPMENT OF VACCINE CANDIDATES THAT HAVE DEMONSTRATED EARLY SCIENTIFIC VALUE BUT HAVE LITTLE COMMERCIAL VALUE, TARGETING DISEASES THAT IMPACT THE WORLD'S MOST VULNERABLE POPULATIONS. SABIN LEVERAGES THE EXPERTISE OF PARTNERS IN THE ACADEMIC, PUBLIC, AND PRIVATE SECTORS, AND PROMOTES OPEN-SOURCE RESEARCH.EBOLA HAS TAKEN THE LIVES OF MORE THAN 15,000 PEOPLE IN THE LAST MANY YEARS. TO PROTECT COMMUNITIES ACROSS THE GLOBE FROM THE CRITICAL THREAT POSED BY EBOLA AND THE CLOSELY RELATED, BUT LESSER KNOWN, MARBURG VIRUS, SABIN IS CURRENTLY DEVELOPING VACCINES FOR EBOLA SUDAN AND MARBURG VIRUS DISEASE BASED ON TECHNOLOGY LICENSED FROM GSK. THE PROPHYLACTIC VACCINE CANDIDATES ARE BASED ON GSK'S PROPRIETARY CHAD3 PLATFORM. IN 2019, THE U.S. HEALTH AND HUMAN SERVICES' BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY AWARDED SABIN A MULTI-YEAR DEVELOPMENT CONTRACT TO ADVANCE DEVELOPMENT OF THE MARBURG AND EBOLA SUDAN VACCINES.

GLOBAL IMMUNIZATION:DESPITE SCIENTIFIC ADVANCES AND INTERNATIONAL SUPPORT, 1.5 MILLION PEOPLE STILL DIE EACH YEAR FROM DISEASES THAT COULD HAVE BEEN PREVENTED BY IMMUNIZATION. SABIN HAS A VISION OF A FUTURE FREE FROM SUCH PREVENTABLE DISEASES. REACHING THIS GOAL REQUIRES EFFICIENT VACCINE DISTRIBUTION, BROAD VACCINE UPTAKE AND EQUITABLE ACCESS TO VACCINATION SERVICES. THROUGH ADVOCACY, CAPACITY DEVELOPMENT AND SOCIAL, BEHAVIORAL, AND EPIDEMIOLOGICAL RESEARCH, SABIN ADVANCES EVIDENCE-BASED STRATEGIES FOR IMPROVED DISTRIBUTION AND UPTAKE OF VACCINES.SABIN'S CAPACITY-DEVELOPMENT ACTIVITIES HELP IMMUNIZATION PROFESSIONALS STAY UP TO DATE ON NEW VACCINES, CHANGING POLICIES AND RECOMMENDATIONS, AND DEVELOPMENTS IN VACCINE SCIENCE; IT ALSO HELPS POLICY MAKERS AND THE PUBLIC TO DISCERN TRUTH FROM FICTION REGARDING VACCINES AND VACCINATION. SABIN'S BOOST GLOBAL COMMUNITY ENABLES IMMUNIZATION PROFESSIONALS TO CONNECT WITH PEERS AND EXPERTS, LEARN SKILLS THAT BUILD CAPACITY AND ADVANCE CAREERS, AND LEAD IMMUNIZATION PROGRAMS IN CHALLENGING CONTEXTS. SABIN'S VACCINE ACCEPTANCE & DEMAND WORKSTREAM HELPS TO DISPEL MISINFORMATION, UNDERSTAND THE SOCIAL DRIVERS OF VACCINATION DECISIONS, AND IMPROVE SOCIAL AND TRADITIONAL MEDIA EFFECTS ON VACCINE CONFIDENCE. SABIN DRIVES VACCINE INNOVATION BY BRINGING TOGETHER BIG THINKERS FROM VARIOUS INDUSTRIES TO ACCELERATE DEVELOPMENT OF A UNIVERSAL INFLUENZA VACCINE. THROUGH WEBINARS, CONFERENCES AND WORKSHOPS SABIN BRINGS TOGETHER RESEARCHERS, GOVERNMENT OFFICIALS, IMMUNIZATION SPECIALISTS AND JOURNALISTS TO SUPPORT THE INTRODUCTION AND EXPANSION OF NEW AND UNDER-UTILIZED VACCINES. SABIN ALSO IMPROVES DISEASE OUTCOMES BY GENERATING ESSENTIAL EPIDEMIOLOGICAL DATA FOR WELL-DESIGNED AND EFFICIENTLY IMPLEMENTED IMMUNIZATION PROGRAMS AND CREATING COST-EFFECTIVE DIAGNOSTICS FOR DISEASES SUCH AS TYPHOID.